SpaceX's newly listed stock has arrived on the market carrying a split personality. On one side sits a satellite internet business that is minting money; on the other, a rocket-and-AI ambition that is still burning through billions. The honest read on whether SPCX has a future is a guarded yes. Starlink is profitable and expanding quickly, yet a net loss of nearly five billion dollars in 2025 and a share price sitting well above a hundred times sales make it one of the most expensive names on Wall Street. That same gap explains why forecasts for the stock scatter so widely between analysts.
Starlink is doing the heavy lifting
Almost everything holding this valuation together traces back to Starlink. The service has grown from a modest 2021 beta test into more than ten million paying subscribers spread across over 160 countries. Revenue climbed to $11.4 billion in 2025, a 48% jump year over year, and the unit now accounts for 69% of the company's total revenue. Crucially, unlike the rocket and AI divisions, Starlink actually turns a profit, posting $4.42 billion in operating income last year, with analysts penciling in something close to $15.5 billion in revenue for 2026. Average revenue per subscriber had been drifting lower, but that trend reversed in May when monthly prices were pushed up by as much as $10. The reach across 160-plus countries matters too, because it turns Starlink into a global utility rather than a niche product, leaving room to keep adding users even as growth in any single market cools. In short, this one line of business does more to justify buying the stock than anything happening at Starbase, and it is the main reason the outlook looks healthier than the balance sheet alone would suggest.
A valuation with almost no margin for error
SPCX has been changing hands between $148 and $175 as of early July 2026, well below the $225.64 peak it touched right after listing. At roughly $2.1 trillion, the company is valued at somewhere between 100 and 130 times sales, a multiple that only makes sense if execution stays near flawless for years on end. The IPO prospectus laid out a net loss of nearly $5 billion, driven mostly by Starship spending and a $6 billion loss inside the AI arm built around xAI and Grok. Even so, Wedbush opened coverage with an Outperform rating and a $190 price target, describing the company as 'a major hyperscaler.' SpaceX's own prospectus framed its ambitions in similar terms, calling one of its bets 'a driving force behind our growth, innovation, and operational success.' That price also bakes in the expectation that the AI and launch businesses eventually earn their keep, something the numbers have not yet demonstrated.
What could move the stock next
There is a near-term, almost mechanical tailwind in play: SPCX joined the Nasdaq-100 on July 7, 2026, a move analysts estimate could funnel roughly $4.3 billion in passive buying as index funds rebalance their holdings. For those funds, inclusion is not a vote of confidence in the business so much as a rule-driven requirement to hold the name, which is why analysts treat the buying as a short-lived boost rather than lasting support. The larger swing factor is Starship, the only vehicle capable of lofting the heavier V3 Starlink satellites. It managed just five flights in 2025 against a stated target of 25, and that shortfall hangs over every projection. The stock also took a hit on July 1, 2026 after a claim surfaced that SpaceX had shown investors a prototype AI handset ahead of the IPO. Musk rejected it immediately, writing on X that day that the story was 'Utterly false.'
So, is it worth buying into
Ultimately, whether SPCX has a future comes down to how much execution risk an investor is willing to shoulder for a slice of a company Musk has placed at the center of space-based AI. Starlink's profits are genuine and show no sign of slowing, but no one has yet proven Starship's reliability or mapped out a clear road to profit for the AI unit. One telling signal on demand: retail investors who asked for large IPO allocations were handed only a fraction of what they requested, a sign that appetite has run ahead of supply. Yet the valuation still has not lined up with the underlying business, in either direction, and that mismatch is exactly what every forecast is trying to price. For a patient holder who can stomach sharp swings, the case answers itself; for everyone else, whether the wait is worth it remains a fair thing to weigh.
